Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RSV vaccine GSK3003892A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 1 of RSV vaccine |
| Group B | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 2 of RSV vaccine |
| Group C | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 3 of RSV vaccine |
| Group D | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 4 of RSV vaccine |
| Group E | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 5 of RSV vaccine |
| Group F | EXPERIMENTAL | Subjects in this group will receive a single dose of formulation 6 of RSV vaccine |
| Group Placebo 1 | PLACEBO_COMPARATOR | Subjects in this group will receive a single dose of placebo |
| Group Placebo 2 | PLACEBO_COMPARATOR | Subjects in this group will receive a single dose of placebo |
| Name | Type | Description |
|---|---|---|
| RSV vaccine GSK3003892A (formulation 1) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003893A (formulation 2) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003895A (formulation 3) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003896A (formulation 4) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003898A (formulation 5) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| RSV vaccine GSK3003899A (formulation 6) | BIOLOGICAL | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
| Placebo comparator | DRUG | Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * A male between, and including, 18 and 44 years of age at the time of vaccination. * Healthy subjects as establis...
RSV vaccine GSK3003892A is an investigational vaccine being studied for the prevention of infections caused by Respiratory Syncytial Virus (RSV). It is being developed for use in healthy adult males aged 18 years and older. The vaccine is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
RSV vaccine GSK3003892A is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety, reactogenicity, and immunogenicity of this investigational RSV vaccine.
RSV vaccine GSK3003892A is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains in early-stage clinical development.
RSV vaccine GSK3003892A has been studied in one completed Phase 1 clinical trial, identified as NCT01905215. This randomized, double-blind, placebo-controlled trial evaluated the safety, reactogenicity, and immunogenicity of the vaccine in 128 healthy adult males aged 18 years and older in Canada.
RSV vaccine GSK3003892A is one of GSK's investigational RSV vaccines. The clinical trial NCT01905215 evaluated multiple investigational RSV vaccines from GSK Biologicals, with GSK3003892A being one of them. No alternative names for this specific vaccine have been disclosed.